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Abstract.
Background: We investigated a sample of cognitively healthy subjects with normal Alzheimer’s disease (AD) cerebrospinal
fluid (CSF) biomarker levels to identify the earliest variables related to longitudinal memory changes.
Objective: Employing a new highly demanding learning and memory test (the Ancient Farming Equipment Test; AFE-T),
we aimed to investigate whether a biomarker related to neurodegeneration (i.e., CSF tau) was associated with longitudinal
memory decline.
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Methods: Thirty-two cognitively and biologically normal (CBN) subjects underwent MRI, neuropsychological assessment,
and the AFE-T at baseline and 18 months later. To explore the relationship between cognitive performance and relevant
factors, a linear model was set up. For a secondary analysis that further explore the effect of tau, the subjects were divided
into CBN-Tau↓ (tau < 228.64 pg/ml; n = 16) and CBN-Tau↑ (tau > 228.64 pg/ml; n = 16). We also performed voxel-based
morphometry (VBM) to identify regions of grey matter volume that would predict both baseline and longitudinal cognitive
performance.
Results: Our main finding was an association between CSF tau and longitudinal memory decline measured with AFE-T
(B = –0.17, p < 0.05; r = –0.414; p < 0.01), and further analyses showed different evolvement between subgroups, with an
accelerated decline in individuals with higher tau (F(1,31) = 8.37; p < 0.01). VBM results suggested that AFE-T performance
is related to grey matter volume in a medial temporal, middle frontal, and posterior cerebellar network at baseline, and that
there are strategic brain areas driving the longitudinal cognitive changes.
Conclusions: The present findings provide evidence for structural and biological markers linked to cognitive aging by
highlighting the role of tau, a marker of neurodegeneration, which can be related with the earliest memory changes in healthy
subjects.
Keywords: Aging, biomarkers, cognition, early detection, memory decline, tau, voxel-based morphometry
INTRODUCTION
Understanding the factors underlying age-related
changes in cognition has long been a challenge. Since
cognitive changes in normal aging and in incipient
pathological processes (e.g., preclinical Alzheimer’s
disease; AD) are closely related, there is a need
to identify the earliest factors driving the cognitive
decline in both populations in order to ensure an early
detection of the pathological processes. While there
is extensive literature on the aging process in large
cohorts of cognitively impaired and unimpaired sub-
jects, we have very little information on biomarkers of
age-related cognitive changes in cognitively healthy
subjects with a confirmed normal AD cerebrospinal
fluid (CSF) biomarker profile.
The cognitive profile in normal aging has been
well-documented in the scientific literature [1–3].
However, one important question that remains open
concerns the factors related to these observed cog-
nitive changes. First, demographic variables such
as age, years of education, and cognitive reserve
[4–6] are known to have an impact on the trajec-
tory of cognition over the life span. A prospective
study involving a large sample of 2,509 cognitively
healthy elderly adults reported that both age and
educational level predicted maintenance of cognitive
function over an 8-year period [7]. Second, some
neuropsychological variables have been identified
as predictors of cognitive decline. Memory decline
has been considered as the major cognitive risk fac-
tor for developing age-related pathologies, such as
mild cognitive impairment (MCI) or AD [8]. Third,
the maintenance of cognitive functioning in aging is
thought to be primarily related to brain maintenance,
that is, relative lack of structural and functional brain
changes [9]. In line with this, a recent report sug-
gested that subjects with larger medial temporal lobe
(MTL) volumes at baseline were more likely to main-
tain their cognitive function over time [10]. Fourth,
biological markers on cognition have been a topic
of intensive research during the last few years. The
most studied AD CSF biomarkers are the tau pro-
tein levels and the 42 amino acid form of amyloid-
(A42). Some studies have suggested that CSF tau
levels rather than A pathology are more closely
related to cognition, specifically to memory decline
[11–13].
Due to the proximity of cognitive changes related
to normal aging versus incipient pathological pro-
cesses, there is an increasing need to develop more
sensitive tests for an early detection of subtle cog-
nitive difficulties in populations at risk. For that
reason, new highly demanding neuropsychological
tests such as the Face Name Associative Memory
Exam [14–16] or the Short-Term Memory Bind-
ing test [17] have been developed. Using previous
research on the neural mechanisms involved in lan-
guage learning and memory, we recently evaluated a
highly demanding learning and memory test called
the Ancient Farming Equipment Test (AFE-T) (for
a review, see Laine & Salmelin [18]). This task
engages the declarative memory system in learning to
associate unfamiliar names (new labels or words) to
completely new objects. To date, the AFE paradigm
has been used to study acquisition of new words
in groups of healthy adults [19, 20] and, in two
studies, in MCI and AD patients [21, 22]. A fMRI
study using the AFE paradigm in an aphasic patient
and in healthy controls showed a clear involvement
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of MTL regions during the learning phase [23]. In
our recent study, we employed the AFE-T to detect
subtle cognitive difficulties in preclinical AD sub-
jects. The AFE-T was found to be a promising tool
for characterizing the cognitive profile of preclinical
AD, being sensitive enough to detect initial learn-
ing difficulties in our at-risk population. Furthermore,
the AFE-T was associated with the CSF A42/tau
ratio [24].
Since there is recent literature regarding the rela-
tionships between cognitive function and AD CSF
biomarkers in cognitively normal subjects [25–29],
the present research pushed further by focusing on a
specific sample of cognitively healthy subjects with
normal AD CSF biomarker levels. The aim of the
present study was to examine and follow up this
well-characterized sample in order to detect demo-
graphical, structural and biological variables related
to the earliest cognitive changes in aging. Employing
the sensitive AFE-T cognitive measure, we specif-
ically wanted to investigate whether a biomarker
related to neurodegeneration (i.e., CSF tau) is associ-
ated with the earliest longitudinal decline of learning




The present participants represent a sub-sample of
Tort-Merino et al. [24], and thus the present methods
description follows that paper. Thirty-two cognitively
healthy subjects with normal AD CSF biomarker lev-
els were included in the present study and followed
up for 18 months. The participants were recruited at
three Spanish memory centers: Hospital Clinic (HC)
and Hospital de la Santa Creu i Sant Pau (HSP) in
Barcelona, as well as the CITA-Alzheimer Founda-
tion (CITA) in San Sebastian. Due to the nature of
this recruitment, some of the subjects included in the
study presented memory complaints. The ethics com-
mittee of the Hospital Clinic of Barcelona approved
the study, and all participants provided a signed,
informed consent before undergoing the neuropsy-
chological assessment, MRI and the lumbar puncture.
All subjects had to meet the following inclusion cri-
teria: a) at least three years of formal education, b)
Mini-Mental State Examination (MMSE) score >24,
and c) Clinical Dementia Rating (CDR) score = 0 and
objective cognitive performance within the normal
range (cutoff 1.5 SD from normative mean) in all tests
on a neuropsychological battery (see below). The fol-
lowing exclusion criteria were applied: a) presence of
any neurological diagnosis, b) presence of a serious or
unstable medical condition, c) diagnosis of a major
psychiatric disorder including schizophrenia, major
depression or substance abuse, and d) presence of any
abnormality in CSF A42, tau, and/or phosphorylated
tau at threonine-181 (ptau) levels.
For a secondary analysis that further explored
the effect of CSF tau in normal aging, we divided
the present sample into CBN-Tau↓ and CBN-Tau↑
subgroups according to their CSF tau levels. These
secondary analyses were done in order to visual-
ize the main findings of the study. The mean of the
CSF tau values (228.64 pg/ml) of the 32 subjects was
used as a cut-off point to ensure an equal distribution
between groups. Subjects with CSF tau levels below
228.64 pg/ml were classified as CBN-Tau↓ (n = 16)
and subjects with CSF tau above 228.64 pg/ml were
included in the CBN-Tau↑ group (n = 16).
Determination of biological and AD CSF
biomarkers
All subjects underwent a lumbar puncture between
9 a.m. and 12 p.m. to collect 10 ml of CSF. The
samples were centrifuged and stored in polypropy-
lene tubes at –80◦C within the first hour after
extraction. CSF A42 levels, tau, and ptau were
measured by enzyme-linked immunosorbent assay
kits (Innogenetics, Ghent, Belgium). Cut-off values
of abnormality for each AD CSF biomarker were
defined according to previous work [30]: a) A42
≤550 pg/ml, b) tau ≥400 pg/ml for subjects between
50–70 years old, and ≥450 pg/ml for subjects older
than 70 years, and c) ptau ≥75 pg/ml. As noted in the
inclusion criteria, all subjects included in the study
presented normal levels for all AD biomarkers. The
AFE-T administrator and the participants were blind
to CSF results.
Apolipoprotein E analysis
Genomic DNA was extracted from peripheral
blood of probands using the QIAamp DNAblood
minikit (Qiagen AG, Basel, Switzerland). APOE
genotyping was performed by polymerase chain
reaction amplification and HhaI restriction enzyme
digestion. Both the AFE-T administrator and the
study participants were blind to the APOE results.
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Neuropsychological assessment
All participants were assessed both at the baseline
and at the follow-up session with a comprehen-
sive neuropsychological battery, administered by a
trained neuropsychologist blind to the CSF results.
The battery encompassed four cognitive domains.
The memory domain included the Free and Cued
Selective Reminding Test (FCSRT) [31], the lan-
guage domain comprised of the Boston Naming Test
[32], and a Semantic Fluency Task [33]; the visual
perception domain contained the Number Location
subtest of the VOSP battery [34]; and the executive
functions domain consisted of the Trail Making Test
[35], the Stroop Test [36], the Symbol Digit Modal-
ities Test [37], and the Digit Span test of the WAIS
[38]. Global cognition was assessed with the MMSE
[39]. Premorbid intelligence was assessed with the
Spanish Word Accentuation Test [40]. Subjective
memory complaints were measured by the Subjec-
tive Cognitive Decline Questionnaire (SCD-Q) [41].
The average time lapse between the baseline neu-
ropsychological assessment and the baseline AFE-T
(list A) was +0.4 (SD 0.6) months and the time lapse
between the follow-up neuropsychological assess-
ment and the follow-up AFE-T (list B) was –0.4 (SD
0.4) months.
The Ancient Farming Equipment Test
The AFE-T called for learning of two lists of new
object/name pairs. For both lists, the objects were
24 black-and-white images of ancient farming equip-
ment taken from the AFE paradigm [18]. Each object
was paired with a pseudoword, that is, a non-existing
word that follows the phonotactic rules of Spanish
[42]. The object names consisted of 14 bisyllabic
and 10 trisyllabic pseudowords that do not exist in
the Spanish dictionary. All stimuli were presented on
a computer screen against a white background using
the E-prime 2.0 version (Psychology Software Tools,
Inc., PA, USA).
The study had a total duration of 18 months and
included a baseline testing session and an 18-month
follow-up. List A was administered at the baseline
assessment and list B at the 18-month follow-up. The
assessments are explained in detail below.
Initial learning sessions, total learning score,
and immediate cued recall
List A was administered in two initial learning ses-
sions that were performed on two consecutive days.
Each learning session included a total of seven runs
and took approximately 45 min. Before starting the
learning phase, each of the 24 object/name pairs was
displayed for seven seconds with a 500 ms pause
between the pairs. The participants were asked to read
aloud the name of the object printed below, and to try
to learn each object/name pair. After the presentation,
the seven learning runs were performed. In each run,
the participants were presented with the objects one
at a time, and were asked to spontaneously say its
name aloud. They were given a maximum of 7 s to
recall the name of each object. After this, the correct
name appeared below the object for 4 s, regardless
of whether the participant had been able to produce
the correct name. The following object was presented
after 500 ms. The order of presentation in each run
was randomized. For each run, the range of scores
was 0–24.
After the last run of the second learning day (i.e.,
total learning score), the immediate cued recall (ICR)
was administered. In this test, each object was pre-
sented one at a time. When the object appeared, the
experimenter verbally provided the first syllable of
the object’s name (phonemic cue). The participant
then had a maximum of 7 s to provide the correct
name. This time feedback (i.e., the correct name) was
not provided after the response.
Follow-up session at 18 months
The 18-month follow-up included exactly the same
procedure as at the baseline except that list B was
administered.
Scoring system
All verbal responses were recorded for offline
scoring. Following the scoring procedure of the
AFE paradigm, a response was considered correct
(score = 1) when (a) the participant recalled the exact
name of the object, or when (b) the name recalled
differed only by a single phoneme from the original
name. Under (b), the following cases were consid-
ered: substitution, addition, or omission of a single
phoneme at any given position of the word, or a
change in position of an otherwise correct phoneme.
This criterion was applied for all runs.
Validation study
A validation study with 30 young adults was con-
ducted to confirm that the word lists A and B had
comparable difficulty. We ran independent t-tests to
explore possible between-group differences between
word lists A and B. In addition, we compared the per-
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formances between the participants of the validation




For each participant, two T1-weighted, high-
resolution, MPRAGE structural MRI (echo time [TE]
2.98 ms, repetition time [TR] 2300 ms, inversion time
900 ms, flip angle 9◦, bandwidth 240 Hz/pixel, matrix
256 × 256, 240 axial slices, isometric voxel size 1/4
1.0 mm3) scans were acquired at the IDIBAPS’s
Imaging core facilities with a 3T whole-body MRI
scanner (Siemens Magnetom Trio; Hospital Clı́nic,
Barcelona).
The mean time between scans was 1.9 (SD 0.2)
years. Three participants were excluded due to severe
motion artifacts.
Processing and analyses
Image processing was performed using the uni-
fied segmentation procedure [43], DARTEL toolbox
[44], and Pairwise Longitudinal Registration [28]
toolbox implemented in SPM12 (Welcome Trust for
Neuroimaging) according to standard procedures.
In the whole sample, we performed whole brain
voxel-based morphometry (VBM) analyses evaluat-
ing which regions of grey matter volume significantly
predicted the total learning score and the immediate
cued recall of the AFE-T at baseline (cross-sectional
VBM, n = 29), as well as their longitudinal change
(longitudinal VBM), using multiple regression within
the SPM12 environment controlling for age and total
intracranial volume.
In the longitudinal VBM analysis, we only
included subjects whose scores declined (n = 20 for
total learning score; n = 23 for immediate cued
recall), because our focus was on identifying the
brain regions associated with impairment over time.
We chose these two measures as they are most
representative of total learning and cued recall,
respectively. We reported results at a threshold
of p < 0.001 uncorrected for multiple comparisons
and used a threshold of p < 0.005 uncorrected for
multiple comparisons for visualization purposes
(http://www.nitrc.org/projects/mricron).
Statistical analyses
Statistical analyses were performed using the SPSS
(v. 22.0) package for Windows. Following the recom-
mendations of the American Physiological Society
[46] and in order to avoid type I errors, alpha value
of p < 0.01 was considered to be significant for all the
comparative analyses.
Whole sample analyses
For the whole sample, demographical data, levels
of CSF A42, CSF tau, and CSF ptau, and APOE
4 frequencies were calculated. Regarding the longi-
tudinal change in both the AFE-T and the standard
neuropsychological tests, repeated-measures anal-
yses of variance (ANOVA) were run in order to
compare baseline and follow-up performances.
Pearson bivariate correlations were calculated to
assess overall associations between the demographic
(age, years of education, and cognitive reserve) and
biological (AD CSF biomarkers) data and the dif-
ference between baseline and follow-up score in
the immediate cued recall of the AFE-T (immediate
cued recall difference score). The difference between
baseline and follow-up in the immediate cued recall
difference score was considered to be the best AFE-T
outcome measure, as it is the final score of the test
(end of the 2nd learning day).
To explore the relationships between the longitu-
dinal memory performance (in both the AFE-T and a
standard neuropsychological test) and relevant fac-
tors, a linear model was set up. The first analysis
included the AFE-T immediate cued recall difference
score as the dependent variable and the second one
included the FCSRT cued recall difference score. For
the second analysis, the FCSRT cued recall differ-
ence score was used as a homologous variable of the
immediate cued recall difference score of the AFE-
T (final cued recall output). Age, the SCD-Q score,
CSF A42, and CSF tau were included as covariates
in both analyses.
Further analyses: differences between
CBN-Tau↑ and CBN-Tau↓
Demographic data, levels of CSF A42, CSF
tau, and CSF ptau, and APOE 4 frequencies were
compared using t-tests for independent samples
and Chi-square analyses when appropriate. We ran
ANOVAs to explore possible cross-sectional differ-
ences between CBN-Tau↑ and CBN-Tau↓ on the
AFE-T at the baseline and at the follow-up assess-
ments.
Regarding the longitudinal change, dependent
samples t-tests were run to compare within-group dif-
ferences between baseline and follow-up scores of the
AFE-T in both CBN-Tau↑ and CBN-Tau↓. Follow-
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up between-group differences were analyzed using
mixed-model ANCOVA controlling for age, years of




Thirty-two cognitively and biologically normal
(CBN) subjects were included in the present study.
Age ranged between 53 and 78 years, and educational
level between 5 and 18 years. Female/male ratio was
62.5/37.5. Regarding the AD CSF biomarker levels,
the mean CSF A42 was 824.1 (SD 210.9) pg/ml
[557.5–1405.0], CSF tau was 228.6 (SD 72.3) pg/ml
[83.5–364.2], and CSF ptau was 50.9 (SD 13.5) pg/ml
[23.5–71.0]. Only 2 subjects (6.2%) were APOE 4
positive (see Table 1).
Variables associated with longitudinal cognitive
decline
Pearson correlations were run in order to find over-
all associations between demographic and biological
data and cognitive changes. The immediate cued
recall difference score (i.e., the difference between
the follow up and baseline score on the final cued
recall output) was used as an indicator of longitu-
dinal cognitive decline. Demographic data such as
age (r = –0.24; p = 0.20), years of education (r = 0.19;
p = 0.29) and cognitive reserve (r = 0.16; p = 0.41)
were not associated with the immediate cued recall
difference score. Neither did the biological variables
of CSF A42 (r = –0.04; p = 0.82) and CSF ptau
(r = –0.24; p = 0.18). However, we found a signifi-
cant negative correlation between CSF tau and the
immediate cued recall difference score (r = –0.414;
p < 0.01; see scatter plot in Fig. 1), indicating worse
recall associated to higher CSF tau levels.
CSF tau driving longitudinal memory changes
The first linear model analysis showed that CSF tau
(B = –0.17; p < 0.05) predicted the performance in the
immediate cued recall difference score of the AFE-
T. Age (B = –0.029; p = 0.705), the SCD-Q score
(B = –0.107; p = 0.155), and CSF A42 (B = 0.002;
p = 0.317) did not predict change on this cognitive
variable. The second model, with the FCSRT cued
recall difference score as the dependent variable, did
not reveal any statistically significant predictors [age
(B = –0.089; p = 0.381), SCD-Q score (B = –0.130;
p = 0.188), CSF A42 (B = –0.003; p = 0.327), and
CSF tau (B = 0.014; p = 0.148)].
Performance in the AFE-T
Validation study
Thirty healthy younger adults were recruited and
randomly divided into two groups (group A, for word
list A; and group B, for word list B). Age ranged
between 17 and 29 years (mean 20.27; SD = 2.57)
and all subjects were college students. There were no
significant differences between the validation groups
on age or educational level.
Importantly for the present purposes, independent
samples t-tests revealed no significant differences
between the validation groups A and B in any of
the learning runs or in the immediate cued recall
(with p-values ranging between 0.20 and 0.86; see
Fig. 2). As expected, when comparing the overall
performances in lists A and B between the valida-
tion subjects and the study participants, significant
differences were found in favor of the younger vali-
dation subjects in both list A (t(14) = 3.74, p < 0.01)
and list B (t(14) = 3.98, p < 0.01).
The AFE-T in the whole sample
We compared baseline and 18-month follow-up
scores of the AFE-T in the whole sample (Table 2;
Fig. 2). ANOVAs showed significant differences
with a better performance in the baseline session in
comparison with the follow-up in the runs 6 (F(1,
31) = 7.13; p < 0.01) and 7 (F(1, 31) = 18.19; p < 0.01)
of the first learning day, and in the runs 1 (F(1,
31) = 13.09; p < 0.01), 2 (F(1, 31) = 7.20; p < 0.01),
7 (i.e., total learning score; F(1, 31) = 7.81; p < 0.01)
and immediate cued recall (F(1, 31) = 7.61; p < 0.01).
Standard neuropsychological tests in the whole
sample
Comparisons of baseline and follow-up scores
on standard neuropsychological tests are shown
in Supplementary Table 1. There was no signifi-
cant difference in global cognition between baseline
and follow-up scores (F(1,30) = 1.37; p = 0.25), as
assessed by the MMSE. Nor was there a signif-
icant difference on the verbal intelligence score
(F(1,30) = 4.12; p = 0.51). Most of the scores obtained
at the follow-up assessment were higher than at the
baseline, even reaching statistical significance for the
free recall subtest of the FCSRT (F(1,30) = 12.25;
p < 0.01).
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Table 1
Demographics, biological data, and AD CSF levels of the whole sample
Demographics Biological data & AD CSF levels
Female/male ratio 62.5/37.5 APOE 4 (% positive) 6.2%
Age 64.6 (SD 6.2) [53–78] A42 824.1 pg/ml (SD 210.9)
Years of education 11.4 (SD 3.8) [5–18] Tau 228.6 pg/ml (SD 72.3)
CRQ 16.6 (SD 4.5) [6–22] ptau 50.9 pg/ml (SD 13.5)
Data are presented as means (SD; standard deviation) and [range]. CSF, cerebrospinal fluid; A42, amyloid-
isoform 42; Tau, total tau; ptau, phosphorylated tau; CRQ, Cognitive Reserve Questionnaire.
Fig. 1. Correlations in the whole sample between CSF tau and CSF pTau levels and the immediate cued recall difference score of the AFE-T.
ICR, immediate cued recall of the AFE-T (difference between baseline and follow-up scores).
Fig. 2. AFE-T baseline and follow-up performance in the whole sample. ICR, immediate cued recall, ∗p < 0.01.
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Table 2
ANOVA of the AFE-T baseline and follow-up scores in the whole sample
Runs List A (N = 32) List B (N = 32) F p
Baseline 18 month F-up
LS1 R1 1.0 (SD 1.2) 0.7 (SD 0.9) 1.55 0.222
LS1 R2 2.2 (SD 2.0) 1.5 (SD 1.6) 4.15 0.050
LS1 R3 3.3 (SD 2.3) 3.0 (SD 2.7) 0.35 0.557
LS1 R4 5.2 (SD 3.7) 4.1 (SD 3.6) 4.46 0.043
LS1 R5 6.6 (SD 4.3) 5.6 (SD 4.3) 3.22 0.083
LS1 R6 8.3 (SD 4.8) 6.6 (SD 5.3) 7.13 0.009∗
LS1 R7 10.0 (SD 5.1) 7.7 (SD 5.6) 18.19 0.001∗∗
LS2 R1 11.2 (SD 5.7) 8.9 (SD 6.5) 13.09 0.001∗∗
LS2 R2 12.1 (SD 6.5) 10.4 (SD 6.9) 7.20 0.009∗
LS2 R3 12.5 (SD 6.6) 11.4 (SD 6.9) 2.70 0.111
LS2 R4 13.8 (SD 6.4) 12.1 (SD 7.3) 5.08 0.031
LS2 R5 14.8 (SD 6.4) 13.7 (SD 7.2) 2.46 0.127
LS2 R6 15.8 (SD 6.7) 14.1 (SD 7.2) 6.46 0.016
LS2 R7 16.1 (SD 6.3) 14.5 (SD 7.3) 7.81 0.009∗
ICR 20.4 (SD 3.8) 19.0 (SD 4.9) 7.61 0.009∗
Data are presented as means (SD; standard deviation). LS1, 1st learning day; LS2, 2nd
learning day; R, learning run number; LS2 R7, total learning score; ICR, immediate
cued recall. ∗p < 0.01; ∗∗p < 0.005.
Further analyses: comparisons between
CBN-Tau↓ and CBN-Tau↑ groups
Group characteristics
Demographic and biological data for both CBN-
Tau↓ and CBN-Tau↑ groups are shown in Table 3.
No differences between CBN-Tau↓ and CBN-Tau↑
groups were found in age (t(30) = 0.80; p = 0.428),
years of education (t(30) = 0.09; p = 0.928), cognitive
reserve (t(26) = –1.03; p = 0.312), or CSF A42 lev-
els (t(30) = 2.04; p = 0.039). There were no significant
differences between groups in terms of gender distri-
bution (χ2 = 0.35; p = 0.554) or in APOE 4 allele
frequency (χ2 = 1.88; p = 0.170). Significant differ-
ences were found in CSF tau (t(30) = 9.32; p < 0.01)
and CSF ptau (t(30) = 6.31; p < 0.01).
Differences between CBN-Tau↑ and CBN-Tau↓
groups
ANOVAs were run to determine whether CBN-
Tau↑ and CBN-Tau↓ groups showed cross-sectional
differences at baseline and/or follow-up performance
in the AFE-T.
There were no significant differences between
groups in either baseline or follow-up performance
(with p values ranging from 0.184 to 0.960 and 0.596
to 0.967, respectively).
Regarding the longitudinal change within each
group, dependent samples t-tests were run in order
to examine differences between baseline and follow-
up learning runs. For CBN-Tau↓, learning runs 5
and 7 of the first learning day of the follow-up
were significantly lower than at the baseline. In the
CBN-Tau↑ group, these differences were found in
the runs 6 and 7 (i.e., total learning score) and in
the immediate cued recall of the second learning
day (Table 4; Fig. 3). When ANCOVAs were run
to analyze longitudinal between-group differences,
the performance difference between the baseline and
follow-up immediate cued recall scores between the
CBN-Tau↓ and CBN-Tau↑ groups revealed that the
CBN-Tau↑ had a larger difference in the immediate
cued recall difference score than the CBN-Tau↓ sub-
jects did (F(1,31) = 8.37; p < 0.01). The differences
in the rest of the learning runs showed no signifi-
cant differences between groups (see Supplementary
Table 2; Fig. 3).
Neuroimaging analyses
We evaluated which regions of grey matter volume
predicted the total learning score and immediate cued
recall of the AFE-T at baseline, as well as their lon-
gitudinal change (total learning score and immediate
cued recall difference scores).
Cross-sectional VBM
At baseline, both total learning score and imme-
diate cued recall showed positive correlations with
grey matter volume in a similar network including
the left and right posterior cerebellar lobes, right and
left medial temporal regions, and the right middle
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Table 3
Demographics, biological data, and AD CSF levels of the CBN-Tau↓ and CBN-Tau↑ groups
Parameters CBN-Tau↓ (n = 16) CBN-Tau↑ (n = 16) t p
Demographics
Gender (% women) 68.8% 56.3% 0.35a 0.554
Age 63.7 (SD 6.7) [53–78] 65.5 (SD 5.6) [56–73] 0.80 0.428
Years of education 11.3 (SD 3.3) [6–18] 11.4 (SD 4.4) [5–18] 0.09 0.928
CRQ 17.7 (SD 4.2) [9–22] 15.9 (SD 4.8) [6–22] –1.03 0.312
Biological data & CSF
APOE 4 (% positive) 0% 12.5% 1.88a 0.170
A42 747.7 pg/ml (SD 231.5) 900.5 pg/ml (SD 161.0) 2.04 0.039
Tau 167.3 pg/ml (SD 39.2) 290.0 pg/ml (SD 35.1) 9.32 0.001∗
ptau 40.8 pg/ml (SD 11.1) 60.9 pg/ml (SD 6.1) 6.31 0.001∗
Data are presented as means (SD; standard deviation). CSF, cerebrospinal fluid; CBN, cognitively and biologically
normal; A42, amyloid- isoform 42; Tau, total tau; ptau, phosphorylated tau; CRQ, cognitive reserve questionnaire.
aχ2 statistic; ∗p < 0.01.
Fig. 3. Comparison of the AFE-T baseline and follow-up performance in the CBN-Tau↓ and CBN-Tau↑ groups. CBN, cognitively and
biologically normal; ICR, immediate cued recall; ∗p < 0.01 (within-group differences); ∗∗p < 0.01 (between-group difference).
occipital gyrus (Fig. 4). For the total learning score,
an additional left middle frontal cluster was a sig-
nificant predictor. No grey matter regions showed a
significant negative correlation with either score.
Longitudinal VBM
The longitudinal decline in both scores correlated
with the rate of grey matter volume reduction in
the right posterior cerebellar lobe (Fig. 4). Volume
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Table 4
Dependent samples t-tests for the AFE-T baseline and follow-up scores of the CBN-Tau↓ and CBN-Tau↑ groups
CBN-Tau↓ (n = 16) CBN-Tau↑ (n = 16)
Runs List A List B t p List A List B t p
Baseline 18 m F-Up Baseline 18 m F-Up
LS1 R1 0.9 (SD 1.4) 0.6 (SD 0.9) 0.77 0.451 1.0 (SD 0.9) 0.7 (SD 0.9) 0.96 0.352
LS1 R2 2.3 (SD 2.1) 1.6 (SD 1.5) 1.96 0.068 2.0 (SD 2.0) 1.4 (SD 1.8) 1.01 0.289
LS1 R3 3.5 (SD 2.6) 3.0 (SD 2.4) 0.67 0.510 3.1 (SD 2.0) 3.0 (SD 3.0) 0.16 0.873
LS1 R4 5.3 (SD 4.6) 3.7 (SD 3.2) 2.33 0.034 5.1 (SD 2.7) 4.4 (SD 4.0) 0.82 0.423
LS1 R5 7.2 (SD 4.8) 5.5 (SD 3.9) 3.36 0.004∗ 6.1 (SD 3.9) 5.7 (SD 4.8) 0.35 0.728
LS1 R6 8.5 (SD 5.7) 6.7 (SD 4.8) 2.83 0.013 8.1 (SD 3.8) 6.6 (SD 5.8) 1.36 0.194
LS1 R7 10.2 (SD 5.7) 8.1 (SD 5.2) 3.29 0.005∗ 9.8 (SD 4.6) 7.4 (SD 6.1) 2.77 0.014
LS2 R1 11.1 (SD 6.4) 8.6 (SD 6.3) 2.64 0.018 11.3 (SD 5.2) 9.2 (SD 6.9) 2.39 0.030
LS2 R2 12.0 (SD 7.1) 10.3 (SD 6.3) 2.28 0.037 12.2 (SD 6.0) 10.4 (SD 7.7) 1.62 0.127
LS2 R3 12.0 (SD 6.7) 11.5 (SD 5.8) 0.59 0.562 13.0 (SD 6.5) 11.2 (SD 8.0) 1.69 0.112
LS2 R4 13.6 (SD 7.2) 12.9 (SD 6.6) 0.62 0.543 14.0 (SD 5.7) 11.4 (SD 8.0) 2.61 0.019
LS2 R5 14.1 (SD 6.7) 14.3 (SD 6.6) –0.21 0.834 15.6 (SD 6.1) 13.2 (SD 8.0) 2.35 0.032
LS2 R6 15.1 (SD 7.6) 14.7 (SD 6.7) 0.55 0.588 16.4 (SD 5.7) 13.5 (SD 7.9) 2.95 0.009∗
LS2 R7 16.0 (SD 6.6) 15.6 (SD 6.8) 0.79 0.437 16.2 (SD 6.2) 13.5 (SD 7.8) 2.96 0.009∗
ICR 19.6 (SD 4.7) 19.6 (SD 5.2) 0.14 0.884 21.2 (SD 2.5) 18.5 (SD 4.9) 3.40 0.004∗
Data are presented as means (SD; standard deviation). CBN, cognitively and biologically normal; LS1, 1st learning day; LS2, 2nd learning
day; R, learning run number; LS2 R7, total learning score; ICR, immediate cued recall. ∗p < 0.01.
Fig. 4. Grey matter volume correlates of the Immediate Cued Recall (A) and Total Learning Score (B) of the AFE-T. Grey matter volume
correlates of the immediate cued recall (A) and total learning score (B) performance on the AFE-T. Green represents cross-sectional
performance at baseline. Hot color represents the correlates of longitudinal change. Results are displayed at a p < 0.005 threshold for
visualization purposes.
reduction in additional clusters in the left insula for
the total learning score, and the left anterior inferior
temporal lobe for the immediate cued recall, corre-
lated with decline in memory performance. All grey
matter volume correlates of cross-sectional and lon-
gitudinal performance on the AFE-T are shown in
Supplementary Table 3.
DISCUSSION
We conducted the first study examining a specific
sample of cognitively healthy subjects with a nor-
mal pattern of AD CSF biomarkers using a highly
demanding learning and memory test and VBM,
with the aim to identify the earliest biological and
structural variables related to longitudinal cognitive
decline in cognitively and biologically normal aging.
Our main finding showed that CSF tau is associated
with longitudinal cognitive changes in this popula-
tion. Furthermore, we found different longitudinal
cognitive patterns by dividing our cohort into two
subgroups based on their CSF tau levels. The VBM
results also suggested that performance on the AFE-T
is related to grey matter volume in a medial tempo-
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ral, middle frontal, and posterior cerebellar network at
baseline, and that there are strategic brain areas driv-
ing the observed longitudinal cognitive changes. Our
findings suggest that there are biological and struc-
tural markers reflecting normal cognitive aging and
highlight the critical impact of tau as a good predic-
tor of the earliest memory decline in healthy subjects
with normal AD CSF biomarkers. Taken together,
since both CSF tau and anatomic MRI are consid-
ered biomarkers of neurodegeneration in the current
ATN classification [47], our results point the pres-
ence of neurodegeneration as a potential predictor of
cognitive change.
In the last few years, the relationships between
biomarkers and cognition have been intensively stud-
ied [25–29, 48] and some studies have suggested a
stronger association between cognition and tau than
between cognition and A [11, 13, 49]. According
to the literature, A accumulates first in the neo-
cortex and then in subcortical areas [50]. Instead,
tau usually concentrates first in the medial tempo-
ral areas [51] that are closely related to encoding
of new information, learning processes and memory.
The main finding of the present study was to find of
an association between CSF tau and the longitudinal
cognitive decline in the AFE-T in a sample of sub-
jects with normal AD CSF biomarker levels. Some
longitudinal studies have found associations between
cognition and tau [12, 49] in cognitively healthy sub-
jects. Hessen et al. [49] studied 122 subjects with
subjective cognitive decline (SCD) and found that
a subgroup presenting memory decline during the
study period had significantly higher CSF tau lev-
els at baseline. However, it has been suggested that
SCD population could have a somewhat higher risk
of developing incipient cognitive decline than con-
trols [52]. Furthermore, a study by Glodzik et al. [12]
found that elevated p-tau231 levels were related to
both decreased memory function and MTL atrophy
in a group of normal elderly subjects that experienced
longitudinal memory decline. Nevertheless, in this
study it is important to note that 1) CSF p-tau231 is
a specific marker of neurofibrillary pathology and 2)
the group with decreased memory function presented
lower levels of the A42/A40 ratio indicating a
noticeable contribution of amyloid deposition. In the
present study, our statistical model showed that SCD
(measured by the SCD-Q) and CSF A42 were not
associated with the immediate cued recall difference
score of the AFE-T, and allowed the identification of
a unique contribution of CSF tau into predicting the
longitudinal memory decline.
An important issue was to further investigate our
main finding regarding the CSF tau impact on the
cognitive performance of cognitively healthy sub-
jects. In this regard, we identified distinct patterns
of cognitive decline in the AFE-T between the two
groups that were established according to their CSF
tau levels. Our findings are enhanced by the fact that
the study groups showed a marginal difference in the
CSF A42 levels in favor of the group with higher tau
levels. This rejects the possibility that A was con-
tributing to the observed cognitive differences and,
again, argues in favor of a unique effect of CSF tau
in the memory function. As seen in Fig. 3, the group
with higher tau levels performed worse in more runs
of the follow-up assessment when compared with the
group exhibiting lower levels of tau. Furthermore,
in their last runs, the lower tau group reached their
baseline performance level, whereas the group with
higher levels of tau remained below their baseline
level throughout the whole follow-up testing. These
results suggest that subjects with lower tau levels
exhibited practice effects in comparison with those
with higher tau. Importantly, the lack of learning
effects has been recently identified as a cognitive
marker of subtle cognitive changes [53], highlight-
ing its importance as a predictive variable of future
cognitive decline. In addition, the change between
the baseline and the follow-up immediate cued recall
showed a significant difference in favor of the lower
tau group. Taken together, our results suggest that
CSF tau levels could have an impact on the learning
and memory functions of cognitively healthy individ-
uals, and that highly demanding memory tests such
as AFE-T could detect this pathological process even
in this population.
Our VBM results also suggest that AFE-T perfor-
mance is related to grey matter volume in a medial
temporal, middle frontal, and posterior cerebellar
network at baseline (cross-sectional VBM, n = 29),
and that there are strategic brain areas driving the
observed longitudinal cognitive changes (longitudi-
nal VBM, n = 20 for total learning score and n = 23
for immediate cued recall). We were able to identify
grey matter regions the volume of which predicted
performance on the AFE-T at baseline, as well as
those in which the longitudinal change in volume pre-
dicted the amount of decline in the studied measures.
Cross-sectional performance at baseline in both total
learning and cued recall measures was associated
with grey matter volume in a medial temporal and
posterior cerebellar network. For the total learning
score, an additional left middle frontal cluster was
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a significant predictor, perhaps reflecting a larger
executive function component than that involved in
cued recall. These results are in line with extensive
previous literature showing that the medial tempo-
ral and prefrontal regions are related to performance
on a variety of memory tasks [54–56]. The predom-
inant brain region involved in both cross-sectional
and longitudinal performance was the posterior cere-
bellum. This finding was unexpected. However, the
role of the posterior cerebellum in a variety of cog-
nitive tasks including language, learning, memory
and especially executive functions such as working
memory and planning is well established [57–61].
The large extension of the cerebellar clusters with
respect to the cortical clusters may be explained by the
healthy cognitive and biological state of our cohort.
In normal aging, the posterior cerebellar lobes show
accelerated volume reduction with respect to other
structures [62], and this reduction may be more rel-
evant to cognitive performance than typically shown
by studies of diseased patients with cortical lesions.
In line with our results, other recent studies includ-
ing similarly aged and cognitively healthy cohorts
[63–65] show involvement of the cerebellum in mem-
ory and executive function tests. Taken together, our
findings showed structural correlates of cognitive
performance in a well-characterized sample of sub-
jects with normal cognition and normal AD CSF
biomarker levels, providing evidence on the most vul-
nerable brain systems related to learning and memory
in aging.
Another important topic of the present work
concerned the sensitivity of cognitive measures
in the assessment of cognitively healthy subjects.
Our whole-sample analyses of the standard neu-
ropsychological tests showed improved follow-up
performance on most of the tasks, suggesting clear
practice effects that are commonly observed in cog-
nitively healthy individuals [53, 66–68]. Practice
effects have been explained by several factors such
as knowledge about testing procedures, previously
learned strategies, and a reduced sense of novelty
and nervousness when re-testing [69]. On the other
hand, our findings on the AFE-T showed a poorer
performance at the follow-up assessment when com-
pared with the baseline, suggesting that the use of a
demanding cognitive measure can alleviate practice
compound that may mask subtle cognitive changes
in cognitively normal subjects. This is crucial for
pinpointing age-related cognitive changes that other-
wise could become underestimated [70]. Importantly
for the present research, our validation study demon-
strated that both baseline and follow-up lists of
stimuli were equally challenging and therefore com-
parable, and thus the observed follow-up changes
could not be explained by list-related differences.
Taken together, our findings support the idea that
standard neuropsychological tests are not sensitive
enough to detect subtle cognitive changes in a cogni-
tively healthy population [71, 72], and suggest that the
AFE-T could be a sensitive task for the early detection
of longitudinal cognitive decline.
This study has some limitations. One important
issue is its small sample size which limits the strength
of the statistical analyses. However, the comprehen-
sive AFE-T protocol allowed for a better and more
fine-grained characterization of learning and mem-
ory processes. With AFE-T, participants’ learning
and memory functions were evaluated using 15 learn-
ing runs at both baseline and follow-up assessments
for both free and cued recall. Regarding the AFE-
T, it is also important to note that only the form A
was administered at baseline and form B at the 18-
month follow-up. Although our pilot study indicated
that lists A and B did not differ in terms of level
of difficulty, it would have been more appropriate to
counterbalance their presentation for the baseline and
follow-up. Another potential limitation of the present
study concerns the multiple comparisons problem
that arises from the large number of statistical com-
parisons performed. This was dealt with post-hoc
Bonferroni corrections, albeit this is an admittedly
conservative method. Moreover, following recom-
mendations [46] to avoid type I errors, alpha level
was set to p < 0.01 for all the comparative analyses.
Finally, considering the novelty of the present find-
ings and the limited sample size, the results have to
be interpreted with caution and replication is called
for in further studies involving larger samples of cog-
nitively and biologically normal subjects.
Conclusions
The present study is the first to show that in a
sample of cognitively healthy individuals with nor-
mal AD CSF biomarker levels, tau, a marker of
neurodegeneration, is associated with longitudinal
cognitive decline. Furthermore, our results pinpoint
critical brain areas related to cross-sectional and
longitudinal learning and memory performance in
this well-characterized sample. Taken together, our
results suggest the presence of neurodegeneration as
a potential predictor of cognitive change in healthy
individuals. The present findings shed light on the
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impact of CSF tau in cognition and provide important
knowledge about the relationships between biolog-
ical status and the earliest age-related cognitive
changes.
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